Proof of principle for epitope-focused vaccine design
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
NMR View: A computer program for the visualization and analysis of NMR data
Johnson, B. A., & Blevins, R. A. (1994) · Journal of Biomolecular NMR · doi:10.1007/bf00404272 · Cited by 3,090
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Protein Structure Prediction Using Rosetta
Rohl, C. A., Strauss, C. E. M., Misura, K. M. S., & Baker, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)83004-0 · Cited by 1,725
Self-citationDesign of a Novel Globular Protein Fold with Atomic-Level Accuracy
Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L., & Baker, D. (2003) · Science · doi:10.1126/science.1089427 · Cited by 1,670
Self-citation
Research works printed but not linked: 1
- Plotkin SA Orenstein WA Offit PA Vaccines 6 Elsevier 2012
Cited by
Items 101–200 of 554
AlphaDesign: A de novo protein design framework based on AlphaFold
Jendrusch, M., Korbel, J. O., & Sadiq, S. K. (2021) · doi:10.1101/2021.10.11.463937 · Cited by 65
“These applications range from the first de novo designed proteins [48] to synthetic vaccines [49, 50], complex assemblies [51, 52] and enzymes [53, 54].”
BackgroundRobert, P. A., Akbar, R., Frank, R., Pavlović, M., Widrich, M., Snapkov, I., Slabodkin, A., Chernigovskaya, M., Scheffer, L., Smorodina, E., et al. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00372-4 · Cited by 78
Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody
Malito, E., Biancucci, M., Faleri, A., Ferlenghi, I., Scarselli, M., Maruggi, G., Surdo, P. L., Veggi, D., Liguori, A., Santini, L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419686111 · Cited by 67
“For example, these insights now raise the possibility for a structural vaccinology approach for the design of a more broadly cross-protective antigen, as described previously for the highly variable meningococcal fHbp (37), and/or represent a starting point for an epitope-focused strategy (38).”
BackgroundPierce, B. G., Boucher, E. N., Piepenbrink, K. H., Ejemel, M., Rapp, C. A., Thomas, W. D., Sundberg, E. J., Weng, Z., & Wang, Y. (2017) · Journal of Virology · doi:10.1128/jvi.01032-17 · Cited by 63
“Such structure-based vaccine design approaches have been explored for other viruses, such as HIV (15, 16), influenza virus (17, 18), and respiratory syncytial virus (RSV) (19, 20), with promising results, though in some cases neutralizing antibodies were not successfully induced in vivo, possibly due to the epitope’s…”
BackgroundAntibody-guided vaccine design: identification of protective epitopes
Lanzavecchia, A., Frühwirth, A., Perez, L. H., & Corti, D. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.001 · Cited by 65
In silico methods for design of biological therapeutics
Roy, A., Nair, S. A., Sen, N., Soni, N., & Madhusudhan, M. S. (2017) · Methods · doi:10.1016/j.ymeth.2017.09.008 · Cited by 68
The promise and challenge of epitope-focused vaccines
Oscherwitz, J. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1160977 · Cited by 65
“capable of targeting conformational or discontinuous neutralizing epitopes have also met with success.(35)”
BackgroundComputational design of a synthetic PD-1 agonist
Bryan, C. M., Rocklin, G. J., Bick, M. J., Ford, A., Majri-Morrison, S., Kroll, A. V., Miller, C. J., Carter, L., Goreshnik, I., Kang, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102164118 · Cited by 61
“In the second design approach, the binding motif was used as a seed around which de novo backbones were generated, as in the Fold-From-Loops (24) protocol.”
Self-citationProtein Crystallography in Vaccine Research and Development
Malito, E., Carfí, A., & Bottomley, M. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613106 · Cited by 69
“Subsequently, a major proof-of-principle that epitope-scaffold immunization can re-elicit neutralizing antibodies against a pre-defined target epitope was obtained by developing new computational methods to design or optimize novel scaffolds tailored for the motavizumab epitope structure [88].”
MethodBrown, A. J., Snapkov, I., Akbar, R., Pavlović, M., Miho, E., Sandve, G. K., & Greiff, V. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00071b · Cited by 59
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
Frei, J. C., Wirchnianski, A. S., Govero, J., Vergnolle, O., Dowd, K. A., Pierson, T. C., Kielian, M. C., Girvin, M. E., Diamond, M., & Lai, J. R. (2018) · Journal of Virology · doi:10.1128/jvi.01023-18 · Cited by 58
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
Dickey, T. H., Tang, W. K., Butler, B., Ouahes, T., Orr-Gonzalez, S., Salinas, N. D., Lambert, L., & Tolia, N. H. (2022) · Science Advances · doi:10.1126/sciadv.abq8276 · Cited by 61
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 61
Havenar-Daughton, C., Carnathan, D. G., Boopathy, A. V., Upadhyay, A. A., Murrell, B., Reiss, S. M., Enemuo, C. A., Gebru, E. H., Choe, Y., Dhadvai, P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.008 · Cited by 58
“…to difficult pathogens, vaccine technologies are becoming more sophisticated, including the development of structurally engineered immunogens (Correia et al., 2014; Sanders et al., 2013), germline-targeting concepts (Escolano et al., 2016; Jardine et al., 2016a; McGuire et al., 2014;…”
Self-citationModeling Immunity with Rosetta: Methods for Antibody and Antigen Design
Schoeder, C. T., Schmitz, S., Adolf‐Bryfogle, J., Sevy, A. M., Finn, J. A., Sauer, M. F., Bozhanova, N. G., Mueller, B. K., Sangha, A. K., Bonet, J., et al. (2021) · Biochemistry · doi:10.1021/acs.biochem.0c00912 · Cited by 64
Self-citationZhang, Y., Kang, R., Zhang, X., Pang, G., Li, L., Han, C., Liu, B., Xue, X., Liu, J., Sun, T., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122147 · Cited by 65
Transplanting Supersites of HIV-1 Vulnerability
Zhou, T., Zhu, J., Yang, Y., Gorman, J., Ofek, G., Srivatsan, S. R., Druz, A., Lees, C. R., Lu, G., Soto, C. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099881 · Cited by 61
Robinson, S. A., Raybould, M. I. J., Schneider, C., Wong, W. K., Marks, C., & Deane, C. M. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009675 · Cited by 46
Next generation of multispecific antibody engineering
Kéri, D., Walker, M., Singh, I., Nishikawa, K. K., & Garcés, F. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad027 · Cited by 80
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
Schiffner, T., Phung, I., Ray, R., Irimia, A., Tian, M., Swanson, O., Lee, J. H., Lee, C.-C. D., Marina-Zárate, E., Cho, S. Y., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01833-w · Cited by 53
Self-citationToward a Human Vaccines Project
Koff, W. C., Gust, I. D., & Plotkin, S. A. (2014) · Nature Immunology · doi:10.1038/ni.2871 · Cited by 56
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets
Servín-Blanco, R., Zamora-Alvarado, R., Gevorkian, G., & Manoutcharian, K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1191718 · Cited by 58
“AVPs will likely need to induce broad and potent cellular immune responses.(5,6) The observation that whole protein anti-”
BackgroundEssentials of de novo protein design: Methods and applications
Marcos, E., & Silva, D. (2018) · WIREs Computational Molecular Science · doi:10.1002/wcms.1374 · Cited by 53
“42 For therapeutics, three-helix bundles were designed to mimic, first, the structure of a viral epitope for vaccine design 43 and, second, scaffold a helix motif — involved in a protein – protein interaction associated with cancer — into a large protein for inhibiting tumor growth 44 (Figure 2m).”
MethodKitiyodom, S., Yata, T., Yostawornkul, J., Kaewmalun, S., Nittayasut, N., Suktham, K., Surassmo, S., Namdee, K., Rodkhum, C., & Pirarat, N. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.09.064 · Cited by 55
Xing, Y., Oliver, S. L., Nguyen, T.-V., Ciferri, C., Nandi, A., Hickman, J., Giovani, C., Yang, E., Palladino, G., Grose, C. F., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501176112 · Cited by 54
“design strategies aimed at eliciting Abs specifically targeting the Fab-RC/Fab-94 epitope could be exploited to induce a potent neutralizing Ab response against VZV infection (31).”
BackgroundDesigning a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus
Fuerst, T. R., Pierce, B. G., Keck, Z., & Foung, S. K. H. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02692 · Cited by 59
Soleymani, S., Tavassoli, A., & Housaindokht, M. R. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105057 · Cited by 63
Bringing immunofocusing into focus
Musunuri, S., Weidenbacher, P. A. B., & Kim, P. S. (2024) · npj Vaccines · doi:10.1038/s41541-023-00792-x · Cited by 57
“Early reports of this approach suggest that it is more straightforward to graft a linear/continuous epitope 108,109 , but recent advances in computation as well as integrating design with directed evolution have enabled grafting of not only linear, but also discontinuous epitopes on to protein…”
BackgroundMousa, J. J., Sauer, M. F., Sevy, A. M., Finn, J. A., Bates, J. T., Alvarado, G., King, H. G., Loerinc, L. B., Fong, R. H., Doranz, B. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609449113 · Cited by 53
“Strategies included a stable trihelix scaffold protein purpose-built to support the helix–loop–helix motif of antigenic site II (FFL_001) (10), a Fab-based scaffold for site II (24), and also a strategy in which the RSV F site II was grafted onto the metapneumovirus (MPV) F protein (RPM-1) to generate a chimeric prote…”
BackgroundMethodResultInfluentialSelf-citationThe Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development
Sun, C., Chen, X., Kang, Y., & Zeng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677027 · Cited by 59
“2013 Multimeric subunit vaccine/tetanus toxoid gp350 (1-470) BALB/c mice Tetrameric gp350 induced ∼20-fold higher serum titers of specific IgG and >19-fold enhancements in neutralizing titers at the highest dose;tetanus toxoid (TT)-specific”
BackgroundMcLeod, B., Mabrouk, M. T., Miura, K., Ravichandran, R., Kephart, S. M., Hailemariam, S., Pham, T., Semesi, A., Kucharska, I., Kundu, P., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.015 · Cited by 56
Zheng, T., & Zhang, C. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14465 · Cited by 61
“Some successful works include novel folds (Kuhlman et al., 2003), enzymes (Fisher et al., 2011), vaccines (Correia et al., 2014), novel protein assemblies (King et al., 2012), ligand-binding proteins (Tinberg et al., 2013), and membrane proteins (Joh et al., 2014).”
BackgroundThe role of circular dichroism spectroscopy in the era of integrative structural biology
Wallace, B. A. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.04.001 · Cited by 51
Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
Tatara, A. M. (2020) · Tissue Engineering Part A · doi:10.1089/ten.tea.2020.0094 · Cited by 53
“This platform of scaffold-based vaccination has also shown efficacy against bacterial pathogens in porcine and murine models.77 Other examples of scaffold-based vaccine systems include those generated from respiratory syncytial virus that were effective in mice as well NHPs.78,79 These particle-based and scaffold-base…”
BackgroundAccurate Calculation of Free Energy Changes upon Amino Acid Mutation
Aldeghi, M., de Groot, B. L., & Gapsys, V. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8736-8_2 · Cited by 58
Residue‐centric modeling and design of saccharide and glycoconjugate structures
Labonte, J. W., Adolf‐Bryfogle, J., Schief, W. R., & Gray, J. J. (2017) · Journal of Computational Chemistry · doi:10.1002/jcc.24679 · Cited by 49
Self-citationIn Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers
Metz, S., Gallichotte, E. N., Brackbill, A., Premkumar, L., Miley, M. J., Baric, R. S., & de Silva, A. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-04767-6 · Cited by 52
The road to a more effective influenza vaccine: Up to date studies and future prospects
Sano, K., Ainai, A., Suzuki, T., & Hasegawa, H. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.08.034 · Cited by 53
Schijns, V. E. C. J., Majhen, D., van der Ley, P., Thakur, A., Summerfield, A., Berisio, R., Nativi, C., Fernández‐Tejada, A., Alvarez-Domínguez, C., Gizurarson, S. S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040501 · Cited by 60
“Rational, structure-guided vaccine design can also involve the development of structurally simpler immunogens that present well-defined minimal epitopes targeted by neutralizing antibodies, serving as epitope mimics for elicitation of more focused immune responses [73].”
BackgroundHIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies
Sliepen, K., & Sanders, R. W. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1129905 · Cited by 51
“In conclusion, no HIV-1 Env epitope-scaffold has yet been able to mount an effective neutralizing response in animals, but the success of an epitope-scaffold in RSV vaccine research has provided a proof-of-concept.[66]”
BackgroundWeidenbacher, P. A. B., & Kim, P. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822062116 · Cited by 47
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate
Ragotte, R. J., Pulido, D., Lias, A. M., Quinkert, D., Alanine, D. G. W., Jamwal, A., Davies, H., Nacer, A., Lowe, E. D., Grime, G. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28601-4 · Cited by 46
Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge
Schickli, J. H., Whitacre, D. C., Tang, R. S., Kaur, J., Lawlor, H. A., Peters, C. J., Jones, J. E., Peterson, D. L., McCarthy, M. P., Nest, G. V., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78450 · Cited by 48
Antibody Epitopes of Pneumovirus Fusion Proteins
Huang, J., Diaz, D., & Mousa, J. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02778 · Cited by 49
Immunomodulatory natural polysaccharides: An overview of the mechanisms involved
Eswar, K., Mukherjee, S., Prabusankar, G., & Rengan, A. K. (2023) · European Polymer Journal · doi:10.1016/j.eurpolymj.2023.111935 · Cited by 54
Structural basis for respiratory syncytial virus and human metapneumovirus neutralization
Miller, R. J., & Mousa, J. J. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101337 · Cited by 63
Pierson, T. C., & Diamond, M. S. (2015) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2014.10.005 · Cited by 45
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
Cai, X., Li, J. J., Liu, T., Brian, O., & Li, J. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab027 · Cited by 50
Can We AlphaFold Our Way Out of the Next Pandemic?
Higgins, M. K. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167093 · Cited by 54
“This insight combined to reveal the chemical nature of the epitopes of the most desirable antibodies, guiding two different approaches to generate improved vaccine immunogens.(12,13) In the first approach, the goal was to produce an intact F protein trimer, locked into the pre-fusion conformation, using insight gained…”
BackgroundNon-human primate models of human respiratory infections
Lemaître, J., Naninck, T., Delache, B., Creppy, J., Huber, P., Holzapfel, M., Bouillier, C., Contreras, V., Martinon, F., Kahlaoui, N., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.04.010 · Cited by 51
Toward rational vaccine engineering
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114142 · Cited by 54
SEMA 2.0: web-platform for B-cell conformational epitopes prediction using artificial intelligence
Ivanisenko, N. V., Shashkova, T. I., Shevtsov, A., Sindeeva, M., Umerenkov, D., & Kardymon, O. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae386 · Cited by 43
“In both cases published by ( 15 ,16 ), the module allows to both identify epitopes as well correctly align the matched residues.”
BackgroundPaths to a malaria vaccine illuminated by parasite genomics
Conway, D. J. (2015) · Trends in Genetics · doi:10.1016/j.tig.2014.12.005 · Cited by 46
Kozlova, E. E. G., Cerf, L., Schneider, F. S., Viart, B. T., NGuyen, C., Steiner, B. T., Lima, S. D. A., Molina, F., Guerra-Duarte, C., Felicori, L. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33298-x · Cited by 49
“These epitopes can be refined for vaccination 51 and their biotechnological applications are well known 1,29 .”
BackgroundGreen, C. A., Sande, C. J., Scarselli, E., Capone, S., Vitelli, A., Nicosia, A., Silva-Reyes, L., Thompson, A. J., de Lara, C. M., Taylor, K. S., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.02.003 · Cited by 45
“[54] [55] [56] [57] In conclusion, we report the first clinical study for replicationdefective viral-vectored RSV vaccines for towards the elderly population in need of protection from severe RSV disease.”
Antibody-guided structure-based vaccines
Kwong, P. D., DeKosky, B. J., & Ulmer, J. B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101428 · Cited by 45
Options and Obstacles for Designing a Universal Influenza Vaccine
Jang, Y. H., & Seong, B. L. (2014) · Viruses · doi:10.3390/v6083159 · Cited by 53
Improving global vaccine accessibility
Hill, A. B., Kilgore, C., McGlynn, M. G., & Jones, C. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.03.002 · Cited by 50
Computationally-driven identification of antibody epitopes
Hua, C. K., Gacerez, A. T., Sentman, C. L., Ackerman, M. E., Choi, Y., & Bailey-Kellogg, C. (2017) · eLife · doi:10.7554/elife.29023 · Cited by 44
“…potent antibody bioactivity is rapidly gaining attention in vaccine design efforts ( Hay-nes, 2015 ; West et al., 2014 ; Zolla-Pazner et al., 2016 ; Correia et al., 2014 ; He et al., 2015 ; Lanzavecchia et al., 2016 ; Pica and Palese, 2013 ; Subbarao and Matsuoka, 2013 ) as well as in reducing…”
BackgroundPritam, M., Singh, G., Swaroop, S., Singh, A. K., Pandey, B. K., & Singh, S. P. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.04.191 · Cited by 47
De novo designed peptides for cellular delivery and subcellular localisation
Rhys, G. G., Cross, J. A., Dawson, W. M., Thompson, H. F., Shanmugaratnam, S., Savery, N. J., Dodding, M. P., Höcker, B., & Woolfson, D. N. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01076-6 · Cited by 44
Epitope specific T‐cell responses against influenza A in a healthy population
Savić, M., Dembinski, J. L., Kim, Y., Tunheim, G., Cox, R. J., Oftung, F., Peters, B., & Mjaaland, S. (2015) · Immunology · doi:10.1111/imm.12548 · Cited by 48
Viral evasion and challenges of hepatitis C virus vaccine development
Pierce, B. G., Keck, Z., & Foung, S. K. H. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.09.004 · Cited by 43
“Rational design of an HCV vaccine The correlation of host antibody response to HCV with viral clearance, coupled with recent successes in structure-based vaccine design for other viruses such as HIV [82,83], RSV [84] and influenza [85], suggests that a rationally designed vaccine that elicits neutralizing antibody res…”
BackgroundRosetta FunFolDes – A general framework for the computational design of functional proteins
Bonet, J., Wehrle, S., Schriever, K., Yang, C., Billet, A., Sesterhenn, F., Scheck, A., Sverrisson, F., Veselkova, B., Vollers, S., et al. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006623 · Cited by 42
Self-citationNguyen, D. N. P., Xu, B., Stanfield, R. L., Bailey, J. K., Horiya, S., Temme, J. S., Leon, D. R., LaBranche, C. C., Montefiori, D. C., Costello, C. E., et al. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00588 · Cited by 42
Kaur, H., Shorie, M., & Sabherwal, P. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112498 · Cited by 41
Target Based Drug Design - A Reality in Virtual Sphere
Verma, S. K., & Prabhakar, Y. S. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150209151209 · Cited by 45
Keck, M.-L., Wrensch, F., Pierce, B. G., Baumert, T. F., & Foung, S. K. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01194 · Cited by 44
Protein Sequence Design with a Learned Potential
Anand-Achim, N., Eguchi, R. R., Mathews, I. I., Perez, C. P., Derry, A., Altman, R. B., & Huang, P.-S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.06.895466 · Cited by 40
“These advances have led to significant achievements in the engineering of therapeutics [13, 14, 15], biosensors [16, 17, 18], enzymes [19, 20, 21, 22], and more [23, 24, 25, 26, 27].”
BackgroundLeveraging deep learning to improve vaccine design
Hederman, A. P., & Ackerman, M. E. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.002 · Cited by 45
Computational protein design — the next generation tool to expand synthetic biology applications
Gainza-Cirauqui, P., & Correia, B. E. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.04.001 · Cited by 44
“Protein design has already delivered a number of hallmark achievements which illustrate the potential of this approach to design functional proteins with potential applications in synthetic biology, such as computationally designed enzymes [6–8], protein-based binders [9], vaccine-like immunogens [10], novel membrane…”
BackgroundSelf-citationThe role of anti‐flavivirus humoral immune response in protection and pathogenesis
Hurtado-Monzón, A. M., Cordero‐Rivera, C. D., Farfán-Morales, C. N., Osuna‐Ramos, J. F., Jesús‐González, L. A. D., Reyes-Ruíz, J. M., & del Ángel, R. M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2100 · Cited by 38
T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases
Song, X., Li, Y., Wu, H., Qiu, H., & Sun, Y. (2024) · Vaccines · doi:10.3390/vaccines12101181 · Cited by 51
“Vaccination is a proven, safe, and cost-effective way to protect against infectious diseases [1,2].”
InfluentialSelf-citationLoomis, R. J., & Johnson, P. (2015) · Vaccines · doi:10.3390/vaccines3020429 · Cited by 37
Self-citationComparison of Rosetta flexible‐backbone computational protein design methods on binding interactions
Loshbaugh, A. L., & Kortemme, T. (2020) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.25790 · Cited by 37
Computational design of structured loops for new protein functions
Kundert, K., & Kortemme, T. (2019) · Biological Chemistry · doi:10.1515/hsz-2018-0348 · Cited by 42
“For the purpose of this review, we will consider loop design as being distinct from the field of loop grafting, which aims to present a fragment of one protein on the scaffold of another, with important applications in vaccine design (Azoitei et al., 2011; Jardine et al., 2013; Correia et al., 2014).”
Designing protein structures and complexes with the molecular modeling program Rosetta
Kuhlman, B. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.aw119.008144 · Cited by 45
“of more effective vaccines (49), the generation of self-assembling protein materials(6), and the design of protein inhibitors and activators for disease relevant signaling pathways (50).”
BackgroundIn Silico Methods in Antibody Design
Zhao, J., Nussinov, R., Wu, W., & Ma, B. (2018) · Antibodies · doi:10.3390/antib7030022 · Cited by 40
“started the vaccine discovery by computational protein design [118].”
Design of proteins presenting discontinuous functional sites using deep learning
Tischer, D., Lisanza, S., Wang, J., Dong, R., Anishchenko, I., Milles, L. F., Ovchinnikov, S., & Baker, D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.29.402743 · Cited by 36
Self-citationHuang, B., Fan, T., Wang, K., Zhang, H., Yu, C., Nie, S., Qi, Y., Zheng, W.-M., Han, J., Fan, Z., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad122 · Cited by 34
“Computational approaches to protein sequence design have been widely used in rational protein engineering, including design of functional enzymes (2, 3), drugs (4, 5), and vaccines (6, 7).”
MethodBates, J. T., Pickens, J. A., Schuster, J. E., Johnson, M., Tollefson, S. J., Williams, J. V., Davis, N., Johnston, R. E., SCHULTZ‐DARKEN, N. J., Slaughter, J. C., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.12.045 · Cited by 37
“Recent advances in understanding the structural biology of RSV F [58, 59] and the computational design of a scaffold antigen that elicits RSV neutralizing antibodies [35] have increased the potential for success with RSV subunit vaccines.”
BackgroundSelf-citationProtein design: from computer models to artificial intelligence
Paladino, A., Marchetti, F., Rinaldi, S., & Colombo, G. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1318 · Cited by 37
Sesterhenn, F., Galloux, M., Vollers, S. S., Csepregi, L., Yang, C., Descamps, D., Bonet, J., Friedensohn, S., Gainza, P., Corthésy, P., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000164 · Cited by 35
“501 While the overall serum neutralization was modest, a monoclonal antibody induced by 502 vaccination, showed superior neutralization potency to that of Palivizumab (21).”
InfluentialSelf-citationChimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune Responses
Debbink, K. M., Lindesmith, L. C., Donaldson, E., Swanstrom, J., & Baric, R. S. (2014) · Journal of Virology · doi:10.1128/jvi.00785-14 · Cited by 39
A critical question for HIV vaccine development: Which antibodies to induce?
Zolla‐Pazner, S. (2014) · Science · doi:10.1126/science.1256526 · Cited by 42
The advent of de novo proteins for cancer immunotherapy
Quijano‐Rubio, A., Ulge, U. Y., Walkey, C., & Silva, D. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.002 · Cited by 41
Pierce, B. G., Keck, Z., Wang, R., Lau, P., Garagusi, K., Elkholy, K. H., Toth, E. A., Urbanowicz, R. A., Guest, J. D., Agnihotri, P., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00704-20 · Cited by 34
“(16, 17) using rationally designed immunogens that optimize presentation of key”
The germinal center antibody response in health and disease
DeFranco, A. L. (2016) · F1000Research · doi:10.12688/f1000research.7717.1 · Cited by 43
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
Boyington, J. C., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Chen, M., Kong, W., Ngwuta, J. O., Thomas, P. V., Tsybovsky, Y., Yang, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159709 · Cited by 34
Self-citationDing, P., Zhang, T., Li, Y., Teng, M., Sun, Y., Liu, X., Chai, S., Zhou, E., Jin, Q., & Zhang, G. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140789 · Cited by 35
“46 Self-assembling protein nanoparticles have been used to achieve targeted display of antigens.”
Self-citationNaïve Human Antibody Libraries for Infectious Diseases
Chan, S. K., Rahumatullah, A., Lai, J. Y., & Lim, T. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_3 · Cited by 40
Cañas‐Arranz, R., Forner, M., Defaus, S., de León, P., Bustos, M. J., Torres, E., Sobrino, F., Andreu, D., & Blanco, E. (2020) · Vaccines · doi:10.3390/vaccines8010019 · Cited by 32
Zhao, Z., Sun, H., Wei, S., Li, B., Feng, Q., Zhu, J., Zeng, H., Zou, Q., & Wu, C. (2015) · Scientific Reports · doi:10.1038/srep12371 · Cited by 38
Structural Features of Antibody-Peptide Recognition
Lee, J. H., Yin, R. M., Ofek, G., & Pierce, B. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910367 · Cited by 40
“hepatitis C virus (HCV) and coronaviruses (12–14), as well as immunotherapeutic antibodies targeting host proteins (15), and structures of those complexes have led to immunogen designs for HCV (16), human immunodeficiency virus (HIV) (17), and respiratory syncytial virus (RSV) (18).”
BackgroundRedesigned HIV antibodies exhibit enhanced neutralizing potency and breadth
Willis, J. R., Sapparapu, G., Murrell, S., Julien, J., Singh, V., King, H. G., Xia, Y., Pickens, J. A., LaBranche, C. C., Slaughter, J. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80693 · Cited by 33
Self-citationRole of artificial intelligence in peptide vaccine design against RNA viruses
Mohanty, E., & Mohanty, A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100768 · Cited by 36
Recent advances in the development of subunit-based RSV vaccines
Jaberolansar, N., Tóth, I., Young, P. R., & Skwarczyński, M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1105134 · Cited by 31
“[105] Therefore, another computational protein design termed Fold From Loops (FFL) was applied.[105] A tree-helix bundle was selected as a protein template because of its similarity to the helix-loop-helix conformation of the motavizumab recognized epitope.”
BackgroundMethodConformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2
Stroh, L. J., Nagarathinam, K., & Krey, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01396 · Cited by 32
“Alternatively, a recent innovative approach termed epitope-focused vaccine design (82, 83) facilitates the design of epitope-specific immunogens to elicit nAbs where conventional vaccines failed to raise an immune response.”
BackgroundRSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine
Hervé, P., Deloizy, C., Descamps, D., Rameix‐Welti, M., Fix, J., McLellan, J. S., Eléouët, J., & Riffault, S. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.006 · Cited by 31
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 40
“, 2019, 2020); these strategies have been used previously for the viral glycoproteins respiratory syncytial virus (RSV) F, influenza hemagglutinin, and HIV envelope proteins (Correia et al., 2014; Crispin et al., 2018; Ofek et al., 2010).”
Metadata
- Authors
- Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., Connell, M. J., Stevens, E., Schroeter, A., Chen, M., MacPherson, S., Serra, A. M., Adachi, Y., Holmes, M. A., Li, Y., Klevit, R. E., Graham, B. S., Wyatt, R. T., Baker, D., Strong, R. K., Crowe, J. E., Johnson, P. R., & Schief, W. R.
- Affiliations
- Scripps Research Institute (US)
- Vanderbilt University Medical Center (US)
- Children's Hospital of Philadelphia (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- National Institutes of Health (US)
- Corresponding author
- Schief, William R.
- ORCID
- Venue
- Nature
- Published
- 2014-02-05
- Volume
- 507
- Issue
- 7491
- Pages
- 201-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4260937
- OpenAlex
- W2040299410
- Cited by
- 555
- References
- 38
- Citations by year
- 2026: 39 · 2025: 40 · 2024: 37 · 2023: 32 · 2022: 55 · 2021: 44 · 2020: 43 · 2019: 45 · 2018: 40 · 2017: 47 · 2016: 50 · 2015: 52 · 2014: 30
- FWCI
- 24.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- Bill and Melinda Gates Foundation
- International AIDS Vaccine Initiative
- March of Dimes Foundation
- Children's Hospital of Philadelphia
- University of Washington
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, San Diego
- National Cancer Institute (T32CA080416)
- National Institute of General Medical Sciences (T32GM007270)
- National Institute of Allergy and Infectious Diseases (P30AI 36214, U54AI057141, U54 AI 005714, R01AI102766, UM1AI100663, R21AI088554, P01AI094419, P30AI036214, P30AI045008)
- Center for AIDS Research, University of California, San Diego
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- RSV vaccine, neutralizing antibodies, computational protein design, protein scaffolds, antigenic determinants, vaccine development
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Antigens, Viral, Enzyme-Linked Immunosorbent Assay, Macaca mulatta, Male, Mice, Inbred BALB C, Models, Molecular, Neutralization Tests, Protein Conformation, Respiratory Syncytial Viruses, Drug Design, Crystallography, X-Ray, Amino Acid Motifs, Respiratory Syncytial Virus Vaccines, Mice, Protein Stability, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.